CrowdStrike (NASDAQ:CRWD – Get Free Report)‘s stock had its “positive” rating reissued by research analysts at Susquehanna in a report issued on Thursday, Benzinga reports. They currently have a $310.00 price objective on the stock. Susquehanna’s price target suggests a potential upside of 3.39% from the company’s previous close. CRWD has been the topic of […]

HC Wainwright reissued their buy rating on shares of Korro Bio (NASDAQ:KRRO – Free Report) in a research report released on Tuesday, Benzinga reports. The firm currently has a $100.00 price objective on the stock. KRRO has been the subject of several other research reports. William Blair assumed coverage on shares of Korro Bio in […]

HC Wainwright reiterated their buy rating on shares of I-Mab (NASDAQ:IMAB – Free Report) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock. I-Mab Stock Down 2.7 % Shares of NASDAQ:IMAB opened at $1.08 on Tuesday. I-Mab has a fifty-two week low […]

HC Wainwright reiterated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $40.00 price target on the biotechnology company’s stock. Capricor Therapeutics Price Performance Shares of CAPR stock opened at $5.05 on Tuesday. Capricor Therapeutics has a 12-month low […]

The Hain Celestial Group (NASDAQ:HAIN – Get Free Report)‘s stock had its “neutral” rating reissued by equities research analysts at Piper Sandler in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $8.00 price target on the stock. Piper Sandler’s price target would indicate a potential upside of […]

Benchmark reiterated their buy rating on shares of Patrick Industries (NASDAQ:PATK – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $145.00 target price on the construction company’s stock. Several other equities analysts also recently weighed in on PATK. Truist Financial lifted their target price […]

HC Wainwright reiterated their buy rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report released on Monday, Benzinga reports. HC Wainwright currently has a $70.00 price target on the stock. Several other equities research analysts also recently weighed in on the company. Wells Fargo & Company started coverage on Disc Medicine […]